In this newly created role, Philip will drive the company's business development, corporate strategy and alliance management to expand clinical opportunities and propel pipeline expansion.
Gutry joined Kronos from Regeneron Pharmaceuticals, where he served as executive director of business development and was responsible for driving the immuno-oncology business development strategy and collaborating with R and D to guide clinical development strategy.
He was previously a principal at MPM Capital where he led company formation and venture investments in oncology companies, and managed MPM's Janssen and Astellas partnerships.
Prior to MPM, Gutry was associate director of corporate development at Gilead Sciences where he focused on mergers and acquisitions and licensing in oncology, respiratory, liver and infectious disease.
Gutry also served as a principal at Riverside Partners, a life sciences focused private equity firm.
The foundation of Kronos was built on over a decade of research into high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology.
By combining small molecule microarrays with extensive know-how in biological assay development, Kronos' technology platform enables high-throughput screens of chemical libraries against target proteins in a more physiologically relevant context.
Kronos's platform has demonstrated its potential to identify compounds that bind or interfere at nanomolar potency with target protein activity directly, disrupt protein-protein or protein-DNA interactions, or indirectly modulate target protein activity by binding to co-factors or other protein complex members.
This approach is ideally suited for rapid discovery of unique ligands that can be utilized in the generation of novel modulators or degraders of historically challenging targets such as transcription factors.
Kronos Bio is focused on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial